Business

Announcement on Voluntary Disclosure of Obtaining Approval Notice for 2 Phase II/III Drug Clinical Trials of iza-bren (EGFR×HER3 Dual-antibody ADC) Combination Therapy in the Treatment of Advanced or Extensive-stage Solid Tumors

Announcement on Voluntary Disclosure of Obtaining Approval Notice for 2 Phase II/III Drug Clinical Trials of iza-bren (EGFR×HER3 Dual-antibody ADC) Combination Therapy in the Treatment of Advanced or Extensive-stage Solid Tumors

articleSichuan Biokin Pharmaceutical Co., Ltd. Class AApril 1, 20265/news/announcement-on-voluntary-disclosure-of-obtaining-approval-notice-for-2-phase-iiiii-drug-clinical-trials-of-iza-bren-egfrher3-dual-antibody-adc-combination-therapy-in-the-treatment-of-advanced-or-extensive-stage-solid-tumors
Announcement on Voluntary Disclosure of Obtaining Approval Notice for 2 Phase II/III Drug Clinical Trials of iza-bren (EGFR×HER3 Dual-antibody ADC) Combination Therapy in the Treatment of Advanced or Extensive-stage Solid Tumors

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of Obtaining Approval Notice for 2 Phase II/III Drug Clinical Trials of iza-bren (EGFR×HER3 Dual-antibody ADC) Combination Therapy in the Treatment of Advanced or Extensive-stage Solid Tumors The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sichuan Biokin Pharmaceutical Co., Ltd. Class A